This publication tested silver infused tooth gel against three of the most problematic of the mouth bacteria and deadly biofilms. This study was completed with the cooperation of multiple divisions of the Texas Tech School of Medicine and Viridis BioPharma. This paper shows the effectiveness of the silver tooth gel in killing pathogenic oral bacteria and eliminating deadly oral biofilms. It should also be noted that the product tested was manufactured by Viridis BioPharma under license from American Biotech Labs and that the product tested was the same as the Silver Biotics Tooth Gel product.

C. albicans was incubated and tested against 10 ppm nanoparticle silver solutions. The percent of reduction is found in the tables, with >90% reduction in most cases.

Analytical Resource laboratories conducted tests on kill time for various fungus/yeast with the results posted in the tables.

The purpose of this white paper is to introduce a product manufactured with patented biotechnology that will lead the next generation of wound care treatment and healing. SilvrSTAT® Antibacterial Wound Dressing Gel is a molecular silver product nanoengineered to provide superior wound management more effectively than any other product on the market.

Armor Gel was applied topically to the wound every time the bandage was changed or brace removed for therapy and the wound healed.

Armor Gel was applied topically to the wound every time the bandage was changed and the wound healed.

ASAP OTC was applied topically to the wound, and it was covered with a bandage. The ASAP OTC was then reapplied every time the bandage was changed and the wound healed.

Our results suggest that capped nanoparticles may serve as useful topical agents for the prevention of infections with pathogens dependent on HS for entry.

Virus infections pose significant global health challenges. The present review focuses on the development of methods for the production of silver nanoparticles and on their use as antiviral therapeutics against pathogenic viruses.

This retrospective study of silver-based therapeutics briefly reviews their history, and then explores the modern application of charged silver particles, especially as an antiviral agent. The recent outbreak of severe acute respiratory syndrome (SARS) suggests this is timely.

Silver nanoparticles have proven to exert antiviral activity against HIV-1 at non-cytotoxic concentrations, but the mechanism underlying their HIV-inhibitory activity has not been not fully elucidated. In this study, silver nanoparticles are evaluated to elucidate their mode of antiviral action against HIV-1 using a panel of different in vitro assays.

This research focuses on evaluating the interaction of silver nanoparticles with a New World arenavirus, Tacaribe virus, to determine if they influence viral replication. Surprisingly exposing the virus to silver nanoparticles prior to infection actually facilitated virus uptake into the host cells, but the silver-treated virus had a significant reduction in viral RNA production and progeny virus release, which indicates that silver nanoparticles are capable of inhibiting arenavirus infection in vitro.

Seven HIV consecutive patients, confirmed by their Western Blot tests, were administered Nanosilver orally (15ml four times daily) for 4 months. All the patients showed a significant increase in their CD4 lymphocyte counts after the treatment. Clinically they were 100% fit and were feeling much better after the treatment period.

Cell lines were treated with 10 and 22 ppm nanoparticle silver solutions and were indistinguishable from the control indicating no cytotoxicity.

The authors conducted a placebo-controlled, single-blind, dose-monitored, cross-over study design in 18 healthy volunteers. After 2 weeks of daily oral silver nanoparticle ingestion, platelet activation was not detectable at peak serum silver concentrations <10ug/L.

The goal of this study was to investigate whether an orally ingested commercially available colloidal silver nanoproduct produces pharmacokinetic interference on select cytochrome P450 enzymes.

ASAP Solutions at both 10 and 22 ppm concentrations have no demonstrated anti-probiotic activity, leaving the body’s natural host defense mechanism intact.

SilverSol completely removes Malaria Parasites from the blood of 100% of the 56 human subjects infected with Malaria in an average of 5 days.

This report concludes the ASAP Solution showed viricidal activity completely eliminating all viral particles in a period of 2.5 hours. The negative control samples showed presence of Phage after 2.5 hours under similar conditions.

5-10 ppm silver does as good a job at stopping the growth of a multitude of bacteria as various antibiotics.

Commercial 10-32 ppm nanoscale silver particle solutions studies were retrospectively reviewed in a single blind, controlled, cross-over with intent-to-treat design. Healthy subjects underwent before and after toxicity testing. No morphological changes or pro-inflammatory cytokine generation were detected.